The University of Southampton
University of Southampton Institutional Repository

No effect of omega-3 fatty acid supplementation on cognition and mood in individuals with cognitive impairment and probable Alzheimer's Disease: a randomised controlled trial.

No effect of omega-3 fatty acid supplementation on cognition and mood in individuals with cognitive impairment and probable Alzheimer's Disease: a randomised controlled trial.
No effect of omega-3 fatty acid supplementation on cognition and mood in individuals with cognitive impairment and probable Alzheimer's Disease: a randomised controlled trial.
Findings from epidemiological and observational studies have indicated that diets high in omega-3 polyunsaturated fatty acids (PUFAs) such as docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) may reduce the risk of cognitive decline and Alzheimer’s disease (AD). To determine if increasing intake of DHA and EPA through supplementation is beneficial to cognition and mood in individuals with cognitive impairment no dementia (CIND) or Alzheimer’s disease (AD) a four month, randomised, double-blind, placebo controlled study was conducted. Fifty-seven participants with CIND and nineteen with AD were randomised to receive either omega-3 PUFAs (600 mg EPA and 625 mg DHA per day) or placebo (olive oil) over a four month period. Elevating depleted levels of EPA and DHA through supplementation in individuals with CIND or AD was found to have negligible beneficial effect on their cognition or mood. These findings confirm an overall negligible benefit of omega-3 PUFA supplementation for those with cognitive impairment and dementia. More intervention studies need to be undertaken with longer study durations and larger sample sizes. It may prove fruitful to examine effects of different doses as well as effects in other dementia subtypes.
alzheimer’s disease (AD), cognitive impairment no dementia (CIND), omega-3 fatty acids, eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA)
1422-0067
24600-24613
Phillips, Michelle A.
0b01ddbc-d1f5-4ff1-b0cb-e55115bdfbcf
Childs, Caroline E.
ea17ccc1-2eac-4f67-96c7-a0c4d9dfd9c5
Calder, Philip C.
1797e54f-378e-4dcb-80a4-3e30018f07a6
Rogers, Peter J.
f6ea7bbf-88b8-4bc4-b8cf-76e8534b3413
Phillips, Michelle A.
0b01ddbc-d1f5-4ff1-b0cb-e55115bdfbcf
Childs, Caroline E.
ea17ccc1-2eac-4f67-96c7-a0c4d9dfd9c5
Calder, Philip C.
1797e54f-378e-4dcb-80a4-3e30018f07a6
Rogers, Peter J.
f6ea7bbf-88b8-4bc4-b8cf-76e8534b3413

Phillips, Michelle A., Childs, Caroline E., Calder, Philip C. and Rogers, Peter J. (2015) No effect of omega-3 fatty acid supplementation on cognition and mood in individuals with cognitive impairment and probable Alzheimer's Disease: a randomised controlled trial. [in special issue: Omega-3 Fatty Acids in Health and Diseases] International Journal of Molecular Sciences, 16 (10), 24600-24613. (doi:10.3390/ijms161024600). (PMID:26501267)

Record type: Article

Abstract

Findings from epidemiological and observational studies have indicated that diets high in omega-3 polyunsaturated fatty acids (PUFAs) such as docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) may reduce the risk of cognitive decline and Alzheimer’s disease (AD). To determine if increasing intake of DHA and EPA through supplementation is beneficial to cognition and mood in individuals with cognitive impairment no dementia (CIND) or Alzheimer’s disease (AD) a four month, randomised, double-blind, placebo controlled study was conducted. Fifty-seven participants with CIND and nineteen with AD were randomised to receive either omega-3 PUFAs (600 mg EPA and 625 mg DHA per day) or placebo (olive oil) over a four month period. Elevating depleted levels of EPA and DHA through supplementation in individuals with CIND or AD was found to have negligible beneficial effect on their cognition or mood. These findings confirm an overall negligible benefit of omega-3 PUFA supplementation for those with cognitive impairment and dementia. More intervention studies need to be undertaken with longer study durations and larger sample sizes. It may prove fruitful to examine effects of different doses as well as effects in other dementia subtypes.

Text
ijms-16-24600 - Version of Record
Available under License Creative Commons Attribution.
Download (724kB)

More information

Accepted/In Press date: 30 September 2015
Published date: 16 October 2015
Keywords: alzheimer’s disease (AD), cognitive impairment no dementia (CIND), omega-3 fatty acids, eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA)
Organisations: Human Development & Health

Identifiers

Local EPrints ID: 384761
URI: http://eprints.soton.ac.uk/id/eprint/384761
ISSN: 1422-0067
PURE UUID: f207ad59-5049-47c9-bdb4-a8aaa21afb8f
ORCID for Caroline E. Childs: ORCID iD orcid.org/0000-0001-6832-224X
ORCID for Philip C. Calder: ORCID iD orcid.org/0000-0002-6038-710X

Catalogue record

Date deposited: 13 Jan 2016 10:28
Last modified: 11 Mar 2021 02:35

Export record

Altmetrics

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×